Neurocrine Biosciences (NBIX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX)

NBIX 141.80

+0.6%

Dec 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1139)	6/8/2003 4:35:42 PM
From: Miljenko Zuanic	Read Replies (1) of 1834

I see very, very slim chance that FDA will reject Indiplon. The question is label, but that will be known by year-end. RE: CEPH I am not CEPH fun. They have two (+one, gabitril) successful drug that they acquired. For Actiq they paid good price. Will they be able to buy fourth one on cheap? Many bios and pharma needs to file hole in pipeline, so for good candidates (and relative reasonable market) biding will increase price. CEPH may make deal with SEPR on Estorra, but they will need to come with very strong and broad marketing plan. This will need big commitment and $$$. So, who knows where is CEPH looking this days??? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next